A growing number of common genetic variants have been robustly and reproducibly associated with type 2 diabetes (T2D). Despite these advances, the precise identity of the genes involved in increasing T2D risk has not yet been established. We propose to use pharmacogenetic and metabolomic approaches to inform the searches for causal variants and better define the molecular pathways involved. By challenging human subjects with a sulfonylurea or with glucose in the presence of metformin we hope to 1) distinguish responses depending on genotype at loci associated with T2D or related glycemic traits, or which impact metabolism of either drug;2) confirm and expand an emerging metabolomic signature of insulin resistance by examining the human response to a glucose load with a larger panel of 380 metabolites (including lipid metabolites), 3) distinguish between the insulin and the glucose components of such response by discriminating the metabolomic profile in response to glucose versus the response to an insulin secretagogue;and 4) evaluate to what extent the refined metabolomic signature is correlated with genetic loci that predict insulin resistance. If successful, this proposal should help clarify the mechanisms by which genetic variants increase risk of T2D, and assess their impact on commonly used therapies. Whether the genetic defect is sufficient to prevent the expected action of either drug, or whether it can be overcome pharmacologically, would both be of clinical interest. In addition, this study should lay the groundwork for a longer outcomes-based pharmacogenetic trial.
Recent studies have identified a growing number of common genetic variants that are reproducibly associated with type 2 diabetes. Despite these advances, the precise identity of the genes involved in increasing diabetes risk has not yet been established, because in most cases the association signals detected merely signal genomic regions that are overrepresented in cases versus controls. We propose to use pharmacogenetic (describing the human response to a pharmacologic perturbation based on the genetic background of the individual) and metabolomic (describing the various metabolites that appear in serum in response to a perturbation) approaches to inform the searches for causal variants and better define the molecular pathways involved.
|Florez, Jose C (2017) The pharmacogenetics of metformin. Diabetologia 60:1648-1655|
|Kim, Seoyoung C; Schneeweiss, Sebastian; Glynn, Robert J et al. (2015) Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study. Ann Rheum Dis 74:1968-75|
|Walford, Geoffrey A; Colomo, Natalia; Todd, Jennifer N et al. (2015) The study to understand the genetics of the acute response to metformin and glipizide in humans (SUGAR-MGH): design of a pharmacogenetic resource for type 2 diabetes. PLoS One 10:e0121553|
|Kim, Seoyoung C; Glynn, Robert J; Liu, Jun et al. (2014) Dipeptidyl peptidase-4 inhibitors do not increase the risk of cardiovascular events in type 2 diabetes: a cohort study. Acta Diabetol 51:1015-23|
|Todd, Jennifer N; Florez, Jose C (2014) An update on the pharmacogenomics of metformin: progress, problems and potential. Pharmacogenomics 15:529-39|
|Franks, Paul W; Pearson, Ewan; Florez, Jose C (2013) Gene-environment and gene-treatment interactions in type 2 diabetes: progress, pitfalls, and prospects. Diabetes Care 36:1413-21|
|Florez, Jose C (2013) Pharmacogenetic perturbations in humans as a tool to generate mechanistic insight. Diabetes 62:3019-21|
|Walford, Geoffrey A; Davis, Jaclyn; Warner, A Sofia et al. (2013) Branched chain and aromatic amino acids change acutely following two medical therapies for type 2 diabetes mellitus. Metabolism 62:1772-8|
|Rhee, Eugene P; Cheng, Susan; Larson, Martin G et al. (2011) Lipid profiling identifies a triacylglycerol signature of insulin resistance and improves diabetes prediction in humans. J Clin Invest 121:1402-11|